SMILES字符串
Nc1nc2ccc(OC(F)(F)F)cc2s1
InChI
1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
InChI key
FTALBRSUTCGOEG-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
生化/生理作用
Glutamate release inhibitor
警示用语：
Danger
危险声明
预防措施声明
危险分类
Acute Tox. 2 Oral
储存分类代码
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
个人防护装备
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
法规信息
新产品
此项目有
R G Miller et al.
Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 4(3), 191-206 (2003-09-18)
Riluzole 100 mg probably prolongs survival in patients with amyotrophic lateral sclerosis by about two months and the safety of the drug is not a major concern. The evidence from randomized controlled trials indicates that patients taking riluzole probably survive
Paul Grant et al.
Journal of child and adolescent psychopharmacology, 20(4), 309-315 (2010-09-03)
The antiglutamatergic drug riluzole (Rilutek) is presently being used off label in the treatment of psychiatric conditions in adult patients and, increasingly, in children. This article briefly reviews the pharmacology of this drug and its current investigative and clinical uses
J J Martino et al.
Oncogene, 32(37), 4366-4376 (2012-10-23)
Non-neuronal expression of components of the glutamatergic system has been increasingly observed, and our laboratory previously had demonstrated the etiological role of ectopically expressed metabotropic glutamate receptor 1 (Grm1/mGluR1) in mouse models of melanoma. We hypothesize that inappropriate glutamatergic signaling
Diana S L Chow et al.
Journal of neurosurgery. Spine, 17(1 Suppl), 129-140 (2012-09-19)
The aim of this paper was to characterize individual and population pharmacokinetics of enterally administered riluzole in a Phase 1 clinical trial of riluzole as a neuroprotective agent in adults 18-70 years old with acute spinal cord injury (SCI). Thirty-five
Christopher Pittenger et al.
CNS drugs, 22(9), 761-786 (2008-08-14)
Recent advances implicate amino acid neurotransmission in the pathophysiology and treatment of mood and anxiety disorders. Riluzole, which is approved and marketed for the treatment of amyotrophic lateral sclerosis, is thought to be neuroprotective through its modulation of glutamatergic neurotransmission.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持